Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

New England Journal of Medicine

Volumn 348, Issue 8, 2003, Pages 702-710

  Bozzette, Samuel A ^a,b,c,e   Ake, Christopher F ^a   Tam, Henry K ^a,b   Chang, Sophia W ^a   Louis, Thomas A ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037456351     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022048     Document Type: Article

References (25)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
3. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
4. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991;40:651-6.
5. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
6. Geffner ME, Yeh DY, Landaw EM, et al. In vitro insulin-like growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr Res 1993; 34:66-72.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
8. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
9. Fisher A, Stenzel M, Fisher AE. Increased prevalence of diabetes mellitus in patients with HIV infection. In: Abstracts of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998:575. abstract.
10. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9.
11. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958.
12. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958-9.
13. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1959.
14. Dube MP, Shankar S, Vanderluitgaren JM, et al. Effect ofindinavir (IDV) monotherapy on endothelial function in men without HIV infection. In: Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002:100. abstract.
15. Huang MB, Hunter M, Bond VC. Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS Res Hum Retroviruses 1999;15:1265-77.
16. Jia H, Lohr M, Jezequel S, et al. Cysteinerich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. Biochem Biophys Res Commun 2001;283:469-79. [Erratum, Biochem Biophys Res Commun 2001;284:245.]
17. Huang MB, Khan M, Garcia-Barrio M, Powell M, Bond VC. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp 120. J Acquit Immune Defic Syndr 2001; 27:213-21.
18. Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 2001;167: 2766-71.
19. Backus L, Mole L, Chang S, Deyton L. The Immunology Case Registry. J Clin Epidemiol 2001;54:Suppl 1:S12-S15.
20. Classification of diseases and functioning & disability. Hyattsville, Md.: National Center for Health Statistics, 2002. (Accessed January 28, 2003, at http://www.cdc.gov/ nchs/icd9.htm.)
21. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag, 2000.
22. Efron B. The efficiency of Cox's likelihood function for censored data. J Am Stat Assoc 1977;72:557-65.
23. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. N Engl J Med 1998;339:1897-904.
24. Currier J, Boyd F, Burtcel B, et al. Accelerated atherosclerosis in men infected with human immunodeficiency virus. Antiviral Ther 2001;6:36. abstract.
25. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and tradeoffs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002;113:229-32.